Attached files
| file | filename |
|---|---|
| S-1 - FORM S-1 - Cascadian Therapeutics, Inc. | v56998orsv1.htm |
| EX-5.1 - EX-5.1 - Cascadian Therapeutics, Inc. | v56998orexv5w1.htm |
| EX-23.1 - EX-23.1 - Cascadian Therapeutics, Inc. | v56998orexv23w1.htm |
| EX-10.49 - EX-10.49 - Cascadian Therapeutics, Inc. | v56998orexv10w49.htm |
Exhibit 23.2
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in this Registration Statement on Form S-1 of our
reports dated May 5, 2010, relating to (i) the consolidated financial statements of Oncothyreon
Inc. (which report expresses an unqualified opinion and includes explanatory paragraphs relating to
the restatement, as discussed in Note 2, and the change in accounting for licensing revenue in
2008, as discussed in Note 2), and (ii) the effectiveness of Oncothyreon Inc.’s internal control
over financial reporting (which report expresses an adverse opinion on the effectiveness of the
company’s internal control over financial reporting because of material weaknesses), appearing in
the Annual Report on Form 10-K of Oncothyreon Inc. for the year ended December 31, 2009.
We also consent to the reference to us under the heading “Experts” in the Prospectus, which is part
of this Registration Statement.
/s/ Deloitte & Touche LLP
Seattle, Washington
October 4, 2010
October 4, 2010